Cognizant (CTSH) Extends Strategic Partnership with Gilead Sciences for Five More Years
Alpha Vantage · GuruFocus · · AI-summarised by FinFlash
Cognizant has extended its strategic partnership with Gilead Sciences for another five years, focusing on enhancing DevOps capabilities and integrating AI tools. The article highlights Cognizant's strong financial health, including an attractive dividend yield of 2.26% and a GF Score™ of 90, suggesting it is significantly undervalued. While insiders have shown net selling, institutional guru ownership indicates confidence in the company's long-term prospects.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.